代文兵助理研究员_

代文兵博士助理研究员

电话/传真：010-82805724

1999～2003：武汉大学药学院药学系，获学士学位；

2003～2006：武汉大学药学院药剂系，获硕士学位；

2006～2009：北京大学药学院药剂学专业，获博士学位；

2009～2012：北京大学基础医学院从事博士后研究工作；

2012年8月，调入北京大学药学院药剂学系任教，助理研究员。

目前承担一项国家自然科学基金项目，并参加了国家重大新药创制新制剂与新释药技术平台、863、973等多项国家基金项目。同时与企业合作开展了多项创新制剂开发工作，承担部分创新药的制剂处方工艺研究。在国内外发表论文10余篇，申请PCT专利一项，申请国内专利5项，已授权3项。

研究兴趣：

肿瘤靶向给药系统；难溶性药物纳米给药系统；创新制剂开发；

发表论文：

1.Dai W, Yang T, Wang Y, Wang X, Wang J, Zhang X, Zhang Q*. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J drug target, 2010, 18: 254.

2.Dai W, Yang T, Wang Y, Wang X, Wang J, Zhang X, Zhang Q*.Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma. Nanomedicine: NMB, 2012, 8(7):1152-61.

3.He S, Cui Z, Mei D, Zhang H, Wang X, Dai W*, Zhang Q. A Cremophor-free self-microemulsified delivery system for intravenous injection of teniposide: evaluation in vitro and in vivo. AAPS PharmSciTech. 2012, 13(3):846-52.

4.Dai W, Jin W, Zhang J, Wang X, Wang J, Zhang X, Wan Y, Zhang Q. Spatiotemporally Controlled Co-delivery of Anti-vasculature Agent and Cytotoxic Drug by Octreotide-Modified Stealth Liposomes. Pharm Res. 2012, 29(10):2902-11.

5.Zhao S, Dai W, He B, Wang J, He Z, Zhang X, Zhang Q*. Monitoring the transport of polymeric micelles across MDCK cell monolayer and exploring related mechanisms. J Control Release, 2012, 160(3): 413-23

6.Zheng N, Dai W, Du W, Zhang H, Lei L, Zhang H, Wang X, Wang J, Zhang X, Gao J, Zhang Q*. A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel to the Tumors with Overexpression of Somatostatin Receptors. Mol. Pharmaceutics, 2012, 9:1175.

7.Liang L, Lin S, Dai W, Lu J, Yang T, Xiang Y, Zhang Y, Li R, Zhang Q*. Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J Control Release. 2012, 3:618-29

8.Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, Ying X, Zhou S, Wang J, Zhang X, Zhang Q*.Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine: NMB, 2012, 8:81-92.